TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.

Tonghua Dongbao Pharmaceutical Co., Ltd.

600867

CNE000000H87

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 16/06/2025			5-day change	1st Jan Change
7.870 ^CNY	-1.50%		+1.81%	-2.36%

05-23	Tibet Trust-Jintong No. 10 Collective Fund Trust Plan managed by Tibet Trust Corporation Limited, Asset Management Arm signed Share Transfer Agreement to acquire 5.7% stake in Xiamen Amoytop Biotech Co., Ltd. from Tonghua Dongbao Pharmaceutical Co., Ltd. for CNY 1.3 billion.	CI
05-22	Tonghua Dongbao Pharma Transfers 5.7% Stake In Amoytop Biotech	RE

Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake

Published on 10/05/2024 at 10:19, updated on 10/05/2024 at 10:35

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Tonghua Dongbao Pharmaceutical Co., Ltd.

Tibet Trust-Jintong No. 10 Collective Fund Trust Plan managed by Tibet Trust Corporation Limited, Asset Management Arm signed Share Transfer Agreement to acquire 5.7% stake in Xiamen Amoytop Biotech Co., Ltd. from Tonghua Dongbao Pharmaceutical Co., Ltd. for CNY 1.3 billion.	05-23	CI
Tonghua Dongbao Pharma Transfers 5.7% Stake In Amoytop Biotech	05-22	RE
Dongbao Pharmaceutical Gets Nod to Sell Diabetes Drug in Nicaragua	05-14	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-29	CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	04-29	CI
Tonghua Dongbao Achieves Primary Endpoints in Phase 2 Trial for Anti-Gout Drugs	04-03	MT
Dongbao Pharmaceutical Gets Uzbekistan Marketing Approval for Blood Sugar Control Product	03-21	MT
Dongbao Pharmaceutical Advances Phase III Trial for Diabetes Injection	03-19	MT
Tonghua Dongbao Pharmaceutical Unit Completes Phase Ib Clinical Trial for Diabetes Drug	02-27	MT
Dongbao Pharma's Unit Finds Positive Results in Weight Loss Drug After Clinical Trial Completion	02-12	MT
Tonghua Dongbao Unit Starts Phase 2 Clinical Study for Anti-Obesity Injection	01-14	MT
Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 27, 2024.	01-02	CI
Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 27,2024, has closed with 23,191,245 shares, representing 1.18% for CNY 180.04 million.	12-30	CI
Adocia and Tonghua Dongbao Pharmaceutical Co. Ltd Announce the Final Dosing in A Phase 3 Clinical Study of Biochaperone®? Lispro	12-12	CI
Tonghua Dongbao Pharmaceutical Completes Phase 1a Trial for Diabetes Injection	12-09	MT
Tonghua Dongbao Pharmaceutical Completes Phase 1 Trial for Type 2 Diabetes Injection	11-11	MT
Tonghua Dongbao Pharmaceutical's Q3 Profit Slides 40%	25/10/24	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24/10/24	CI
Sisram Medical Names CFO	14/10/24	MT
Sisram Medical Ltd Announces Appointment of Jiahong LI New Chief Financial Officer, Effective 29 October 2024	14/10/24	CI
Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 27, 2024.	08/10/24	CI
Huachuang Securities Downgrades Tonghua Dongbao Pharmaceutical to Add From Strong Buy; Price Target is 10.30 Yuan	02/09/24	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	30/08/24	CI
Tonghua Dongbao Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	26/08/24	CI
Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 9, 2024.	21/08/24	CI

Chart Tonghua Dongbao Pharmaceutical Co., Ltd.

Duration

Period

Chart Tonghua Dongbao Pharmaceutical Co., Ltd.

600867: Dynamic Chart

TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.

Employees

3,410

Sector

Pharmaceuticals

Calendar

08-19 - Q2 2025 Earnings Release (Projected)

More about the company